Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study
Corresponding Author
Elena Zerkalenkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Correspondence
Elena Zerkalenkova, Laboratory of Cytogenetics and Molecular Genetics, Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Email: [email protected]
Search for more papers by this authorSvetlana Lebedeva
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Department of Fundamental Medicine, Moscow State University named after M.V. Lomonosov, Moscow, Russia
Search for more papers by this authorAnna Kazakova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorGrigory Tsaur
Regional Children’s Hospital No. 1, Yekaterinburg, Russia
Research Institute of Medical Cell Technologies, Yekaterinburg, Russia
Search for more papers by this authorYulia Starichkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorNatalia Timofeeva
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorOlga Soldatkina
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorEvgenia Aprelova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorAleksandr Popov
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorNatalia Ponomareva
Russian Children’s Clinical Hospital, Moscow, Russia
Search for more papers by this authorLudmila Baidun
Russian Children’s Clinical Hospital, Moscow, Russia
Search for more papers by this authorClaus Meyer
Institute of Pharmaceutical Biology, Diagnostic Centre of Acute Leukemia (DCAL), Goethe-University of Frankfurt, Frankfurt/Main, Germany
Search for more papers by this authorGalina Novichkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorMichael Maschan
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorAleksey Maschan
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorRolf Marschalek
Institute of Pharmaceutical Biology, Diagnostic Centre of Acute Leukemia (DCAL), Goethe-University of Frankfurt, Frankfurt/Main, Germany
Search for more papers by this authorYulia Olshanskaya
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorCorresponding Author
Elena Zerkalenkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Correspondence
Elena Zerkalenkova, Laboratory of Cytogenetics and Molecular Genetics, Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Email: [email protected]
Search for more papers by this authorSvetlana Lebedeva
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Department of Fundamental Medicine, Moscow State University named after M.V. Lomonosov, Moscow, Russia
Search for more papers by this authorAnna Kazakova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorGrigory Tsaur
Regional Children’s Hospital No. 1, Yekaterinburg, Russia
Research Institute of Medical Cell Technologies, Yekaterinburg, Russia
Search for more papers by this authorYulia Starichkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorNatalia Timofeeva
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorOlga Soldatkina
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorEvgenia Aprelova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorAleksandr Popov
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorNatalia Ponomareva
Russian Children’s Clinical Hospital, Moscow, Russia
Search for more papers by this authorLudmila Baidun
Russian Children’s Clinical Hospital, Moscow, Russia
Search for more papers by this authorClaus Meyer
Institute of Pharmaceutical Biology, Diagnostic Centre of Acute Leukemia (DCAL), Goethe-University of Frankfurt, Frankfurt/Main, Germany
Search for more papers by this authorGalina Novichkova
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorMichael Maschan
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorAleksey Maschan
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorRolf Marschalek
Institute of Pharmaceutical Biology, Diagnostic Centre of Acute Leukemia (DCAL), Goethe-University of Frankfurt, Frankfurt/Main, Germany
Search for more papers by this authorYulia Olshanskaya
Dmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Search for more papers by this authorAbstract
Introduction
Translocations involving the KMT2A gene (also known as MLL) are frequently diagnosed in pediatric acute leukemia cases with either lymphoblastic or myeloid origin. KMT2A is translocated to multiple partner genes, including MLLT10/AF10 localizing at chromosomal band 10p12. KMT2A-MLLT10 is one of the common chimeric genes diagnosed in acute leukemia with KMT2A rearrangement (8%), especially in acute myeloid leukemia (AML; 18%). MLLT10 is localized in very close proximity to two other KMT2A partner genes at 10p11-12—NEBL and ABI1, so they could not be distinguished by conventional cytogenetics.
Methods
In this work, we present a cohort of 28 patients enrolled into Russian Pediatric AML registration study carrying rearrangements between chromosomal regions 11q23.3 and 10p11-12. G-banding, FISH, reverse transcription PCR, and long-distance inverse PCR were used to characterize the KMT2A gene rearrangements in these patients.
Results
We demonstrate that 25 patients harbor the KMT2A-MLLT10 rearrangement, while three patients show the rare KMT2A rearrangements (2× KMT2A-NEBL; 1× KMT2A-ABI1).
Conclusions
Therefore, the combination of cytogenetic and molecular genetic methods is of high importance in diagnosing cases with t(10;11)(p11-12;q23.3).
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
Supporting Information
| Filename | Description |
|---|---|
| ijlh12969-sup-0001-TableS1-S2.docxapplication/docx, 40.3 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A. 1991; 88(23): 10735-10739.
- 2Emerenciano M, Koifman S, Pombo-de-Oliveira MS. Acute leukemia in early childhood. Braz J Med Biol Res. 2007; 40: 749-760.
- 3Huret JL, Dessen P, Bernheim A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia. 2001; 15: 987-989.
- 4Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391-2405.
- 5Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120: 3187-3205.
- 6Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018; 32: 273.
- 7Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011; 25: 1239-1248.
- 8Coser VM, Meyer C, Basegio R, Menezes J, Marschalek R, Pombo-de-Oliveira MS. Nebulette is the second member of the nebulin family fused to the MLL gene in infant leukemia. Cancer Genet Cytogenet. 2010; 198: 151-154.
- 9Taki T, Shibuya N, Taniwaki M, et al. ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLL gene in acute myeloid leukemia with t(10;11)(p11.2;q23). Blood. 1998; 92: 1125-1130.
- 10Shibuya N, Taki T, Mugishima H, et al. t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: specific expression patterns of ABI1 gene in leukemia and solid tumor cell lines. Genes Chromosomes Cancer. 2001; 32: 1-10.
- 11den Nijs JI, Gonggrijp HS, Augustinus E, Leeksma CH. Hot bands: a simple G-banding method for leukemic metaphases. Cancer Genet Cytogenet. 1985; 15: 373-374.
- 12 ISCN 2016. An International System for Human Cytogenomic Nomenclature (2016). Basel, Switzerland: Karger Publishers; 2016.
- 13Jansen MW, van der Velden VH, van Dongen JJ. Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia. 2005; 19: 2016-2018.
- 14Meyer C, Schneider B, Reichel M, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A. 2005; 102: 449-454.
- 15Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet. 2007; 16: 92-106.
- 16Benedikt A, Baltruschat S, Scholz B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 2011; 25: 135-144.
- 17Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121: 167-178.
- 18Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001; 15: 2343-2360.
- 19Van Limbergen H, Poppe B, Janssens A, et al. Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia. Leukemia. 2002; 16: 344-351.
- 20Emerenciano M, Renaud G, Sant'Ana M, Barbieri C, Passetti F, Pombo-de-Oliveira MS. Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies. Leuk Res. 2011; 35: 1001-1007.
- 21Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002; 87: 250-256.
- 22Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000; 18: 1295-1300.
- 23Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira MS. The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia. Br J Haematol. 2013; 161: 224-236.
- 24Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009; 114: 2489-2496.
- 25Moncman CL, Wang K. Nebulette: a 107 kD nebulin-like protein in cardiac muscle. Cell Motil Cytoskeleton. 1995; 32: 205-225.
- 26Maiellaro-Rafferty K, Wansapura JP, Mendsaikhan U, et al. Altered regional cardiac wall mechanics are associated with differential cardiomyocyte calcium handling due to nebulette mutations in preclinical inherited dilated cardiomyopathy. J Mol Cell Cardiol. 2013; 60: 151-160.
- 27Purevjav E, Varela J, Morgado M, et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol. 2010; 56: 1493-1502.
- 28Li B, Zhuang L, Trueb B. Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J Biol Chem. 2004; 279: 20401-20410.
- 29Deng XA, Norris A, Panaviene Z, Moncman CL. Ectopic expression of LIM-nebulette (LASP2) reveals roles in cell migration and spreading. Cell Motil Cytoskeleton. 2008; 65: 827-840.
- 30Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell. 1996; 85: 853-861.
- 31Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997; 16: 4226-4237.
- 32DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood. 2002; 99: 3780-3785.
- 33Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008; 14: 355-368.
- 34Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011; 152: 141-154.
- 35Bursen A, Schwabe K, Ruster B, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010; 115: 3570-3579.
- 36Emerenciano M, Kowarz E, Karl K, et al. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential. Cancer Lett. 2013; 332: 30-34.
- 37Shi Y, Alin K, Goff SP. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 1995; 9: 2583-2597.
- 38Garcia-Cuellar MP, Schreiner SA, Birke M, Hamacher M, Fey GH, Slany RK. ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+. Oncogene. 2000; 19: 1744-1751.
- 39Cui M, Yu W, Dong J, Chen J, Zhang X, Liu Y. Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Med Oncol. 2010; 27: 632-639.
- 40Kumar S, Lu B, Dixit U, et al. Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma. Oncotarget. 2015; 6: 37792-37807.
Citing Literature
